- Olon outlined its 2026 development plan at DCAT Week, focusing on expanding manufacturing capacity and capabilities across the US, India, Italy, and France.
- The plan includes investments in API production, biologics development, and bioconjugation capacity to support complex therapies, including antibody–drug conjugates (ADCs).
Olon has outlined its 2026 development plan during DCAT Week, detailing a series of investments and infrastructure upgrades across its global network in the United States, India, Italy, and France. The initiative focuses on expanding capacity, enhancing technology platforms, and increasing operational flexibility to support the development and manufacturing of complex therapies.
The plan includes region-specific efforts. In the United States, the company is working to strengthen scale-up and integrated manufacturing capabilities. In India, investments are directed toward expanding active pharmaceutical ingredient (API) production to support supply continuity. In Italy, Olon aims to reinforce capabilities in high-potency APIs (HPAPIs) and chemical manufacturing, while also increasing microbial fermentation capacity to support biologics and complex therapies.
In France, the company is nearing completion of a new bioprocess development suite. The facility is designed to enhance upstream and downstream development and scale-up of recombinant proteins, including monoclonal antibodies and antibody–drug conjugates. It will also double bioconjugation capacity through a multi-purpose suite supporting both clinical and commercial manufacturing of bioconjugates.
These developments form part of Olon’s broader strategy to operate as an integrated CDMO and contract manufacturing partner for ADCs. The Saint-Julien site complements earlier investments in payload and linker synthesis at the Rodano facility, enabling the company to cover the full value chain from toxin and payload production to final drug substance manufacturing.
“Our strategy is focused on expanding capabilities that are critical for the development of complex therapies and sustainable manufacturing, combining innovation with operational excellence across key technology platforms.”
Paolo Tubertini, CEO of Olon
